Similar articles

• Blood eosinophil levels as a biomarker in COPD.

  Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, Barnes N, Hilton E. Brusselle G, et al. Respir Med. 2018 May;138:21-31. doi: 10.1016/j.rmed.2018.03.016. Epub 2018 Mar 15. Respir Med. 2018. PMID: 29724389 Review.
• Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease.

  Zeiger RS, Tran TN, Butler RK, Schatz M, Li Q, Khatry DB, Martin U, Kawatkar AA, Chen W. Zeiger RS, et al. J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):944-954.e5. doi: 10.1016/j.jaip.2017.10.004. Epub 2017 Nov 15. J Allergy Clin Immunol Pract. 2018. PMID: 29153881
• Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.

  Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K. Vestbo J, et al. Int J Chron Obstruct Pulmon Dis. 2019 Apr 16;14:853-861. doi: 10.2147/COPD.S189585. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31114183 Free PMC article.
• Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations.

  Djamin RS, Bafadhel M, Uzun S, Russell REK, Ermens AAM, Kerstens R, Aerts JGJV, Pavord ID, van der Eerden MM. Djamin RS, et al. Respir Med. 2019 Jul-Aug;154:27-33. doi: 10.1016/j.rmed.2019.06.005. Epub 2019 Jun 8. Respir Med. 2019. PMID: 31203097 Clinical Trial.
• Blood eosinophils in COPD: friend or foe?

  Papaporfyriou A, Bakakos P, Hillas G, Papaioannou AI, Loukides S. Papaporfyriou A, et al. Expert Rev Respir Med. 2022 Jan;16(1):35-41. doi: 10.1080/17476348.2021.2011219. Epub 2021 Dec 3. Expert Rev Respir Med. 2022. PMID: 34821191 Review.